AB0385 THE EFFECTIVENESS OF THE ANTI-TUMOR NECROSIS FACTOR THERAPY INFLIXIMAB IN NEURO-BEHCET’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Background: The use and benefit of biologic targeted therapy in the treatment refractory manifestations behcet’s syndrome remain unclearly defined due to relative paucity published research. Neuro-behcet’s disease represents a challenging clinical presentation. lack identified effective strategies management neuro-behcet’s adds burden contributes tight control. [1-3] Objectives: aim this systematic review meta-analysis is examine effect anti-TNF on NBD by performing previously studies assessing effectiveness patients with BD having or recurrent neurological manifestations. Methods: Authors used PICO Model (P= population, I= intervention, C= comparator, O= outcome) for designing research question. PRISMA statement was developing study protocol search methodology. Literature searches were done articles English language only from January 2000 till 2020 (considering first last available publication that addresses question satisfied eligibility criteria). registered Prospero PROSPERO website reviews meta-analysis. Random-effects performed. Inter-study heterogeneity explored using I2 statistics. Cumulative conducted assess temporal trend accumulating evidence accruing studies. Meta-regression analyze possible confounders. current worked simple score “Hamdy Woldeamanuel response score, 2020”, behind incorporate standard evaluation parameters assessment responses driven measures each study. authors numerical values grade pattern parameter considered attempting standardize quantification minimize tendency towards overestimation. included radiographic points rated scale 5. Results: Twenty-one involving 64 included, 52 male patient 12 females at ratio 4.3:1, mean age 38 .21 years, duration 84.76 5 months. Effect size analysis showed 59 out i.e. 93.7% treated responders infliximab (CI 88% - 99.3%). There no significant inter-study (I2 = 0%, p 0.744). favoring increasing over 20 years. statistically confounding (p 0.89), sex 0.29), 0.67). Conclusion: In Infliximab strong therapeutic disease. an observed two decades which may be improved diagnostic accuracy. References: [1]Uygunoğlu U, Siva A. Behçet’s Syndrome Nervous System Involvement. Curr Neurol Neurosci Rep . 2018;18(7):35. Published 2018 May 23. doi:10.1007/s11910-018-0843-5. [2]Ohno S, Ohguchi M, Hirose Matsuda H, Wakisaka A, Aizawa M. Close Association HLA-Bw51 With Disease. Arch Ophthalmol. 1982; 100(9):1455–1458. doi:10.1001/archopht.1982.01030040433013. [3]Kalra, S., Silman, A., Akman-Demir, G., et al. Diagnosis Neuro-Behçet’s disease: international consensus recommendations. Journal neurology, 2014; 261(9): 1662–1676. https://doi.org/10.1007/s00415-013-7209-3 Figure 1 a. Forest plot summarizing results treat Neurobehcet Overall, 94% responded infliximab. Disclosure Interests: None declared